MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial. The new data ...
Armed with positive results in two phase 3 trials, MSD is poised to be the first drugmaker to file for approval of an oral PCSK9 inhibitor for lowering cholesterol. Top-line results from the CORALreef ...
Dive into intense multiplayer action with **“Takeover Raid: Conquering An Entire Clan Base Grid.”** In this video, we showcase a high-stakes raid where an entire clan’s base grid is taken over, ...
Buy Power Grid Corporation of India; target of Rs 324: Prabhudas Lilladher Feb 04 2026 12:35 PM Power Grid shares jump 8% after firm raises FY26 capex guidance to Rs 32,000 crore Feb 02 2026 03:37 PM ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...